BJDX BJDX
Company Profile ↓Company Overview
BJDX (BJDX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -79.26% |
| 6 Months: | -61.13% |
| 3 Months: | -35.92% |
| 1 Month: | -14.48% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 249.04K | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | 48.91K | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -148.17K | -233.20K | -666.07K | -957.99K | -2.07M | -1.99M | -2.81M | -2.68M | -2.90M | -2.34M | -2.43M | -1.90M | -1.36M | -1.89M | -1.99M | -1.62M | -1.94M |
| Net Income | -127.99K | -194.19K | 640.23K | -1.19M | -2.01M | -1.94M | -2.96M | -2.54M | -2.81M | -2.30M | -2.33M | -2.48M | -1.48M | -1.86M | -1.96M | -1.60M | -1.92M |
| Diluted EPS | - | - | -0.15 | -0.11 | -0.10 | -2.00 | -2.94 | -2.49 | -22.00 | -16.67 | -394.76 | -256.16 | -76.94 | -13.46 | -1.41 | -1.01 | -1.95 |
| R&D Expense | 2.72K | 24.18K | 225.99K | 442.53K | 694.76K | 756.28K | 1.38M | 1.35M | 1.68M | 1.40M | 1.33M | 1.03M | 551.65K | 784.80K | 889.90K | 785.61K | 811.84K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 249.04K | - | - | - |
| Gross Profit | - | - | 48.91K | - | - | - |
| Operating Income | -1.20M | -3.23M | -9.32M | -10.31M | -7.17M | -6.95M |
| Net Income | -1.16M | -3.49M | -9.30M | -9.95M | -7.72M | -6.85M |
| Diluted EPS | - | -0.41 | -9.22 | -3,631.48 | -456.75 | -15.25 |
| R&D Expense | 527.25K | 1.15M | 4.15M | 5.71M | 3.47M | 3.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.52M | 21.02M | 13.52M | 4.87M | 6.66M | 7.12M |
| Total Equity | -2.93M | -4.21M | 20.38M | 11.54M | 2.89M | 5.73M | 5.98M |
| Cash & Equivalents | - | 912.36K | 19.05M | 10.11M | 2.21M | 4.30M | 5.16M |
| Total Liabilities | - | 1.85M | 637.16K | 1.98M | 1.97M | 927.92K | 1.14M |
| Current Liabilities | - | - | 637.16K | 1.64M | 1.77M | 810.37K | 1.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -508.71K | -4.37M | -7.74M | -8.31M | -7.82M | -6.05M |
| Investing Cash Flow | - | -23.95K | -1.20M | -704.17K | -306.78K | -173.74K |
| Financing Cash Flow | 1.33M | 22.53M | 8.07K | 1.11M | 10.22M | 7.09M |
| Capital Expenditure | - | -23.95K | -1.20M | -704.17K | -306.78K | -173.74K |
| Free Cash Flow | - | -4.39M | -8.94M | -9.02M | -8.13M | -6.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 19.6% | - | - | - |
| Operating Margin % | - | - | -3,741.5% | - | - | - |
| Net Margin % | - | - | -3,733.1% | - | - | - |
| ROE % | 27.5% | -17.1% | -80.6% | -343.8% | -134.7% | -114.6% |
| ROCE % | - | -15.8% | -78.4% | -332.9% | -122.6% | -115.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BJDX
$BJDX stock is up 34% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPa3NOVFRNTVVfWEI1cWs4bTEzRnNZaThhMWV0cUJUam5nUFh2REpDUmlYaFJwRkZFa211NXN6bVhkNkNDNGFDa2RKMnFLV1RTbmNxZnczaVZqT1hZRHBLeFdhNngzVnk4ZDlMZmtVQ19aTWVoZDdjMl9CUExtLUtHcWtMdXhlbm04blFieW…
BJDX Stock Dips As Pivotal Sepsis Trial Finishes Enrollment Early - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPOU9rZVFJVTZvbXd3VlVkOUxNZlN5VEFqWU1pTHhYOFJVSllTNHpVVGJuRnpkbFJWTGVDcUhod0l1R2RLV2xDVGdvOGlVV0pocXRJV2JwUWllUFNDU0VpN0VBUHJXZ0tGV19sYTIzTDlXSjJfd2t5d1pqeExqV3JfOGx3?oc=5" target=…
BJDX Stock Dips As Pivotal Sepsis Trial Hits Key Milestone - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOQ1haMFN2VTJkVWRNX1laM0I3MXhiQ3ZWcmtSdmJETXJORXZGTjZtY3BkUjRiTDVzNHJMdEVJNVpqVk16b21ZQXZCOER4WV9CN1ozSGN5c0J3Vkh1eXVnNGZWTW5BLVpWek5iZUhzQ2s5aExhX2lmMFI2Y1d5WDlabzlRbDBqUQ?oc=5" t…
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQZk4xcEVhZmZmUHpNNUpBMnZYNlczaUlGM2xMU3hGWUk4S3VrenB2UlhsdVNqdEdHdEtnbjUyUTZSa0d5Z25WVWVUU001NUh4aUhxTElJaXkwS1QwUDN2S1piU1FORXdVcVhXakwyaVBLcUVHdXlPSDUxcDQ4Q0NFeW50OUM5cHBuWTlNVE…
Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions - TechStock²
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxORFh1X3BnMlJILTZBMHUxU2F4VGZQNmpCRlA5MzUyN180Q1cwZXAwVU1Wb3dlalllUkl4ejVSQ0JLbVc3WXJDMzQxdkJ4TnE1OXFKZHRHZHhOQUxtR3pqVDVsbXhTa2NZWF9TUmg5MFNjQnNITkxGTDlmNUlFSDJubjN2SzV5N3pGTmhxSX…
BJDX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1jZjYxd25zeTJmcjMtb0x4MVVQTTlnS3VhaFFxSzAxZDVlZGN3OC11SkZIQktuR244VGozZ1VMZ0J4dEtqb0E?oc=5" target="_blank">BJDX</a> <font color="#6f6f6f">Finviz</font>…
BJDX — Frequently Asked Questions
What is the current share price of BJDX?
As of 2026-08-05 17:25 PDT, BJDX trades at $1.24 on NASDAQ/NYSE. Its 52-week range is $0.86 to $14.00.
What is the P/E ratio of BJDX?
BJDX trades at a trailing price-to-earnings (P/E) ratio of -0.08.
What is the return on equity (ROE) of BJDX?
BJDX has a return on equity (ROE) of -114.61%. Its return on capital employed (ROCE) is -115.88%.
Is BJDX a good stock to buy?
This page provides a data-driven analysis of BJDX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.